PDF(Pubmed)
Abstract：
UNASSIGNED: Breast cancer is the most prevalent cancer among women worldwide and is a well-known cause for cancer mortality in females. COX-2 (cyclooxygenase) plays a vital role in development of some human cancers such as lung, colon and breast. It is a potent enzyme that is important for the conversion of arachidonic acid into prostaglandins. These prostaglandins mediate cellular proliferation, apoptosis and angiogenesis which contributes to carcinogenesis. Overexpression of COX-2 has been detected in several malignancies including breast cancer. COX-2 overexpression is regarded as a poor prognostic marker of breast cancer.The present study will aim to study the immunohistochemical expression of COX-2 in breast cancer and compare it with known histopathological parameters thus assessing its prognostic value.
UNASSIGNED: This will be an observational study conducted in the Department of Pathology, JNMC, Wardha (Sawangi). Radical mastectomy specimens will be studied for COX-2 expression by immunohistochemistry in patients diagnosed with breast carcinoma. COX-2 expression will be quantified as immunohistochemical score and results will be correlated with various histopathological parameters.
UNASSIGNED: The expected result of our study will suggest an association of COX-2 expression to the factors associated with poor prognosis in breast carcinoma. A positive correlation is expected between larger tumor size, positive lymph node status, higher T stage and N stage and lymphovascular invasion.
UNASSIGNED: Conclusions will be drawn from the obtained results of the immunohistochemical study by using COX-2- for detection of overexpression of COX-2 when evaluated with TNM staging, histological grading and molecular types of breast cancer.
UNASSIGNED: This will be an observational study conducted in the Department of Pathology, JNMC, Wardha (Sawangi). Radical mastectomy specimens will be studied for COX-2 expression by immunohistochemistry in patients diagnosed with breast carcinoma. COX-2 expression will be quantified as immunohistochemical score and results will be correlated with various histopathological parameters.
UNASSIGNED: The expected result of our study will suggest an association of COX-2 expression to the factors associated with poor prognosis in breast carcinoma. A positive correlation is expected between larger tumor size, positive lymph node status, higher T stage and N stage and lymphovascular invasion.
UNASSIGNED: Conclusions will be drawn from the obtained results of the immunohistochemical study by using COX-2- for detection of overexpression of COX-2 when evaluated with TNM staging, histological grading and molecular types of breast cancer.
摘要：
乳腺癌是全球女性中最普遍的癌症，也是女性癌症死亡率的众所周知的原因。COX-2（环氧合酶）在某些人类癌症的发展中起着至关重要的作用，例如肺癌，结肠和乳房。它是一种有效的酶，对花生四烯酸转化为前列腺素很重要。这些前列腺素介导细胞增殖，细胞凋亡和血管生成有助于致癌作用。在包括乳腺癌在内的几种恶性肿瘤中已经检测到COX-2的过表达。COX-2过表达被认为是乳腺癌预后不良的标志物。本研究旨在研究COX-2在乳腺癌中的免疫组织化学表达，并将其与已知的组织病理学参数进行比较，从而评估其预后价值。
■这将是在病理学系进行的一项观察性研究，JNMC,Wardha(Sawangi)。将通过免疫组织化学研究乳腺癌根治术标本中COX-2的表达。COX-2表达将定量为免疫组织化学评分,并且结果将与各种组织病理学参数相关联。
■我们研究的预期结果将表明COX-2表达与乳腺癌不良预后相关的因素有关。预计较大的肿瘤大小之间存在正相关，阳性淋巴结状态，较高的T期和N期和淋巴管浸润。
■当用TNM分期评估时，将通过使用COX-2检测COX-2过表达的免疫组织化学研究结果得出结论，乳腺癌的组织学分级和分子类型。
■这将是在病理学系进行的一项观察性研究，JNMC,Wardha(Sawangi)。将通过免疫组织化学研究乳腺癌根治术标本中COX-2的表达。COX-2表达将定量为免疫组织化学评分,并且结果将与各种组织病理学参数相关联。
■我们研究的预期结果将表明COX-2表达与乳腺癌不良预后相关的因素有关。预计较大的肿瘤大小之间存在正相关，阳性淋巴结状态，较高的T期和N期和淋巴管浸润。
■当用TNM分期评估时，将通过使用COX-2检测COX-2过表达的免疫组织化学研究结果得出结论，乳腺癌的组织学分级和分子类型。
